Skip to main content
Erschienen in: Annals of Surgical Oncology 3/2007

01.03.2007

Short-Term Exposure of Cancer Cells to Micromolar Doses of Paclitaxel, with or without Hyperthermia, Induces Long-Term Inhibition of Cell Proliferation and Cell Death In Vitro

verfasst von: John Michalakis, Spyros D. Georgatos, Eelco de Bree, Hara Polioudaki, John Romanos, Vassilis Georgoulias, Dimitris D. Tsiftsis, Panayiotis A. Theodoropoulos

Erschienen in: Annals of Surgical Oncology | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

ABSTRACT

Background

During intraoperative hyperthermic intraperitoneal chemotherapy for primary or secondary peritoneal malignancies, tumor cells are exposed to high drug concentrations for a relatively short period of time. We investigated in vitro the effect of paclitaxel and hyperthermia on cell proliferation, cell cycle kinetics and cell death under conditions resembling those during intraoperative hyperthermic intraperitoneal chemotherapy.

Methods

Human breast MCF-7, ovarian SKOV-3 and hepatocarcinoma HEpG2 cells were exposed to 10 and 20 μM paclitaxel at 37, 41.5 or 43°C for 2 h. Cell proliferation, cell cycle kinetics, necrosis and apoptosis were evaluated.

Results

Hyperthermia exerted a cytostatic effect to all cell lines and at 43°C a cytotoxic effect on MCF-7 cells. MCF-7 and SKOV-3 cells treated under normothermic conditions with paclitaxel were arrested at G2/M or M phase for at least 3 days. Most of MCF-7 cells and approximately half of SKOV-3 cells were in interphase and became multinucleated without properly completing cytokinesis. Hyperthermia at 41.5°C altered cell cycle distribution and affected the paclitaxel-related effect on cell cycle kinetics of MCF-7 and SKOV-3 cells. Analysis of the mode of cell death showed that cell necrosis prevailed over apoptosis. Hyperthermia at 43°C increased paclitaxel-mediated cytotoxicity in MCF-7 cells and to a lesser extent in SKOV-3 and HEpG2 cells.

Conclusions

Short-time treatment of carcinoma cells with high (micromolar) concentrations of paclitaxel in normothermic and hyperthermic conditions is highly efficient for cell growth arrest and could be of clinical relevance in locoregional chemotherapy.
Literatur
1.
Zurück zum Zitat Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 2004; 4:277–83CrossRef Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 2004; 4:277–83CrossRef
2.
Zurück zum Zitat Hofstra LS, de Vries EGE, Mulder NH, Willemse PHB. Intraperitoneal chemotherapy in ovarian cancer. Cancer Treat Rev 2000; 26:133–43PubMedCrossRef Hofstra LS, de Vries EGE, Mulder NH, Willemse PHB. Intraperitoneal chemotherapy in ovarian cancer. Cancer Treat Rev 2000; 26:133–43PubMedCrossRef
3.
Zurück zum Zitat de Bree E, Rosing H, Michalakis J, et al. Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination. Eur J Surg Oncol 2006; 32:666–70 de Bree E, Rosing H, Michalakis J, et al. Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination. Eur J Surg Oncol 2006; 32:666–70
4.
5.
Zurück zum Zitat Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am 2003; 12:605–21PubMedCrossRef Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am 2003; 12:605–21PubMedCrossRef
6.
Zurück zum Zitat Ohashi N, Kodera Y, Nakanishi H, et al. Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastases as revealed by GFP-tagged human gastric cancer cell lines in nude mice. Int J Oncol 2005; 27:637–44PubMed Ohashi N, Kodera Y, Nakanishi H, et al. Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastases as revealed by GFP-tagged human gastric cancer cell lines in nude mice. Int J Oncol 2005; 27:637–44PubMed
7.
Zurück zum Zitat Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003; 21:4560–7PubMedCrossRef Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003; 21:4560–7PubMedCrossRef
8.
Zurück zum Zitat Stewart JH IV, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. Ann Surg Oncol 2005; 12:765–77PubMedCrossRef Stewart JH IV, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. Ann Surg Oncol 2005; 12:765–77PubMedCrossRef
9.
Zurück zum Zitat Witkamp AJ, de Bree E, Van Goethem R, Zoetmulder FAN. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev 2001; 27:365–74PubMedCrossRef Witkamp AJ, de Bree E, Van Goethem R, Zoetmulder FAN. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev 2001; 27:365–74PubMedCrossRef
10.
Zurück zum Zitat Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am 2003; 12:689–701PubMedCrossRef Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am 2003; 12:689–701PubMedCrossRef
11.
Zurück zum Zitat Mohamed F, Marchettini P, Stuart OA, Urano M, Sugarbaker PH. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol 2003; 10:463–8PubMedCrossRef Mohamed F, Marchettini P, Stuart OA, Urano M, Sugarbaker PH. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol 2003; 10:463–8PubMedCrossRef
12.
Zurück zum Zitat Cividalli A, Cruciani G, Livdi E, Pasqualetti P, Tirindelli Danesi D. Hyperthermia enhances the response of paclitaxel and radiation in a mouse adenocarcinoma. Int J Radiat Oncol Biol Phys 1999; 44:407–12PubMedCrossRef Cividalli A, Cruciani G, Livdi E, Pasqualetti P, Tirindelli Danesi D. Hyperthermia enhances the response of paclitaxel and radiation in a mouse adenocarcinoma. Int J Radiat Oncol Biol Phys 1999; 44:407–12PubMedCrossRef
13.
Zurück zum Zitat Leal BZ, Meltz ML, Mohan N, Kuhn J, Prihoda TJ, Herman TS. Interaction of hyperthermia with Taxol in human MCF-7 breast adenocarcinoma cells. Int J Hyperthermia 1999; 15:225–36PubMedCrossRef Leal BZ, Meltz ML, Mohan N, Kuhn J, Prihoda TJ, Herman TS. Interaction of hyperthermia with Taxol in human MCF-7 breast adenocarcinoma cells. Int J Hyperthermia 1999; 15:225–36PubMedCrossRef
14.
Zurück zum Zitat Michalakis J, Georgatos SD, Romanos J, Koutala H, Georgoulias V, Tsiftsis D, Theodoropoulos PA. Micromolar taxol, with or without hyperthermia, induces mitotic catastrophe and cell necrosis in HeLa cells. Cancer Chemother Pharmacol 2005; 56:615–22PubMedCrossRef Michalakis J, Georgatos SD, Romanos J, Koutala H, Georgoulias V, Tsiftsis D, Theodoropoulos PA. Micromolar taxol, with or without hyperthermia, induces mitotic catastrophe and cell necrosis in HeLa cells. Cancer Chemother Pharmacol 2005; 56:615–22PubMedCrossRef
15.
Zurück zum Zitat Othman T, Goto S, Lee JB, Taimura A, Matsumoto T, Kosaka M. Hyperthermic enhancement of the apoptotic and antiproliferative activities of paclitaxel. Pharmacology 2001; 62:208–12PubMedCrossRef Othman T, Goto S, Lee JB, Taimura A, Matsumoto T, Kosaka M. Hyperthermic enhancement of the apoptotic and antiproliferative activities of paclitaxel. Pharmacology 2001; 62:208–12PubMedCrossRef
16.
Zurück zum Zitat van Bree C, Savonije JH, Franken NA, Haveman J, Bakker PJ. The effect of p53-function on the sensitivity to paclitaxel with or without hyperthermia in human colorectal carcinoma cells. Int J Oncol 2000; 16:739–44PubMed van Bree C, Savonije JH, Franken NA, Haveman J, Bakker PJ. The effect of p53-function on the sensitivity to paclitaxel with or without hyperthermia in human colorectal carcinoma cells. Int J Oncol 2000; 16:739–44PubMed
17.
Zurück zum Zitat Rietbroek RC, Katschinski DM, Reijers MH, et al. Lack of thermal enhancement for taxanes in vitro. Int J Hyperthermia 1997; 13:525–33PubMedCrossRef Rietbroek RC, Katschinski DM, Reijers MH, et al. Lack of thermal enhancement for taxanes in vitro. Int J Hyperthermia 1997; 13:525–33PubMedCrossRef
18.
Zurück zum Zitat Knox JD, Mitchel RE, Brown DL. Effects of taxol and taxol/hyperthermia treatments on the functional polarization of cytotoxic T lymphocytes. Cell Motil Cytoskeleton 1993; 24:129–38PubMedCrossRef Knox JD, Mitchel RE, Brown DL. Effects of taxol and taxol/hyperthermia treatments on the functional polarization of cytotoxic T lymphocytes. Cell Motil Cytoskeleton 1993; 24:129–38PubMedCrossRef
19.
Zurück zum Zitat Sharma D, Chelvi TP, Kaur J, Ralhan R. Thermosensitive liposomal taxol formulation: heatmediated targeted drug delivery in murine melanoma. Melanoma Res 1998; 8:240–4PubMedCrossRef Sharma D, Chelvi TP, Kaur J, Ralhan R. Thermosensitive liposomal taxol formulation: heatmediated targeted drug delivery in murine melanoma. Melanoma Res 1998; 8:240–4PubMedCrossRef
20.
Zurück zum Zitat Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience. Semin Oncol 1997; 24(5 Suppl 15):S15–26–9 Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience. Semin Oncol 1997; 24(5 Suppl 15):S15–26–9
21.
Zurück zum Zitat de Bree E, Romanos J, Michalakis J, Relakis K, Georgoulias V, Melissas J, Tsiftsis DD. Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin. Anticancer Res 2003; 23:3019–27PubMed de Bree E, Romanos J, Michalakis J, Relakis K, Georgoulias V, Melissas J, Tsiftsis DD. Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin. Anticancer Res 2003; 23:3019–27PubMed
22.
Zurück zum Zitat de Bree E, Rosing H, Beijnen JH, Romanos J, Michalakis J, Georgoulias V, Tsiftsis DD. Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer. Anticancer Drugs 2003; 14:103–10PubMedCrossRef de Bree E, Rosing H, Beijnen JH, Romanos J, Michalakis J, Georgoulias V, Tsiftsis DD. Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer. Anticancer Drugs 2003; 14:103–10PubMedCrossRef
24.
25.
Zurück zum Zitat Mickey B, Howard J. Rigidity of microtubules is increased by stabilizing agents. J Cell Biol 1995; 130:909–17PubMedCrossRef Mickey B, Howard J. Rigidity of microtubules is increased by stabilizing agents. J Cell Biol 1995; 130:909–17PubMedCrossRef
26.
Zurück zum Zitat Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993; 90:9552–6PubMedCrossRef Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993; 90:9552–6PubMedCrossRef
27.
Zurück zum Zitat Danesi R, Figg WD, Reed E, Myers CE. Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. Mol Pharmacol 1995; 47:1106–11PubMed Danesi R, Figg WD, Reed E, Myers CE. Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. Mol Pharmacol 1995; 47:1106–11PubMed
28.
Zurück zum Zitat Theodoropoulos PA, Polioudaki H, Kostaki O, Derdas SP, Georgoulias V, Dargemont C, Georgatos SD. Taxol affects nuclear lamina and pore complex organization and inhibits import of karyophilic proteins into the cell nucleus. Cancer Res 1999; 59:4625–33PubMed Theodoropoulos PA, Polioudaki H, Kostaki O, Derdas SP, Georgoulias V, Dargemont C, Georgatos SD. Taxol affects nuclear lamina and pore complex organization and inhibits import of karyophilic proteins into the cell nucleus. Cancer Res 1999; 59:4625–33PubMed
29.
Zurück zum Zitat Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996; 56:816–25PubMed Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996; 56:816–25PubMed
30.
Zurück zum Zitat Bogdan C, Ding A. Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages. J Leukoc Biol 1992; 52:119–21PubMed Bogdan C, Ding A. Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages. J Leukoc Biol 1992; 52:119–21PubMed
31.
Zurück zum Zitat Ding AH, Porteu F, Sanchez E, Nathan CF. Shared actions of endotoxin and taxol on TNF receptors and TNF release. Science 1990; 248:370–2PubMedCrossRef Ding AH, Porteu F, Sanchez E, Nathan CF. Shared actions of endotoxin and taxol on TNF receptors and TNF release. Science 1990; 248:370–2PubMedCrossRef
32.
Zurück zum Zitat Lee LF, Schuerer-Maly CC, Lofquist AK, et al. Taxol-dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer. Cancer Res 1996; 56:1303–8PubMed Lee LF, Schuerer-Maly CC, Lofquist AK, et al. Taxol-dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer. Cancer Res 1996; 56:1303–8PubMed
33.
Zurück zum Zitat Moos PJ, Fitzpatrick FA. Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc Natl Acad Sci USA 1998; 95:3896–901PubMedCrossRef Moos PJ, Fitzpatrick FA. Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc Natl Acad Sci USA 1998; 95:3896–901PubMedCrossRef
34.
Zurück zum Zitat Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 1999; 401:616–20PubMedCrossRef Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 1999; 401:616–20PubMedCrossRef
35.
Zurück zum Zitat Erenpreisa JE, Ivanov A, Dekena G, et al. Arrest in metaphase and anatomy of mitotic catastrophe: mild heat shock in two human osteosarcoma cell lines. Cell Biol Int 2000; 24:61–70PubMedCrossRef Erenpreisa JE, Ivanov A, Dekena G, et al. Arrest in metaphase and anatomy of mitotic catastrophe: mild heat shock in two human osteosarcoma cell lines. Cell Biol Int 2000; 24:61–70PubMedCrossRef
36.
Zurück zum Zitat Merlin JL, Bour-Dill C, Marchal S, Bastien L, Gramain MP. Resistance to paclitaxel induces time-delayed multinucleation and DNA fragmentation into large fragments in MCF-7 human breast adenocarcinoma cells. Anticancer Drugs 2000; 11:295–302PubMedCrossRef Merlin JL, Bour-Dill C, Marchal S, Bastien L, Gramain MP. Resistance to paclitaxel induces time-delayed multinucleation and DNA fragmentation into large fragments in MCF-7 human breast adenocarcinoma cells. Anticancer Drugs 2000; 11:295–302PubMedCrossRef
37.
Zurück zum Zitat Panvichian R, Orth K, Day ML, Day KC, Pilat MJ, Pienta KJ. Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance. Cancer Res 1998; 58:4667–72PubMed Panvichian R, Orth K, Day ML, Day KC, Pilat MJ, Pienta KJ. Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance. Cancer Res 1998; 58:4667–72PubMed
38.
Zurück zum Zitat Torres K, Horwitz SB. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 1998; 58:3620–6PubMed Torres K, Horwitz SB. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 1998; 58:3620–6PubMed
39.
Zurück zum Zitat Blajeski AL, Kottke TJ, Kaufmann SH. A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines. Exp Cell Res 2001; 270:277–88PubMedCrossRef Blajeski AL, Kottke TJ, Kaufmann SH. A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines. Exp Cell Res 2001; 270:277–88PubMedCrossRef
40.
Zurück zum Zitat Yeung TK, Germond C, Chen X, Wang Z. The mode of action of taxol: apoptosis at low concentration and necrosis at high concentration. Biochem Biophys Res Commun 1999; 263:398–404PubMedCrossRef Yeung TK, Germond C, Chen X, Wang Z. The mode of action of taxol: apoptosis at low concentration and necrosis at high concentration. Biochem Biophys Res Commun 1999; 263:398–404PubMedCrossRef
41.
Zurück zum Zitat Chen JG, Yang CP, Cammer M, Horwitz SB. Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Cancer Res 2003; 63:7891–9PubMed Chen JG, Yang CP, Cammer M, Horwitz SB. Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Cancer Res 2003; 63:7891–9PubMed
42.
Zurück zum Zitat Abal M, Souto AA, Amat-Guerri F, Acuna AU, Andreu JM, Barasoain I. Centrosome and spindle pole microtubules are main targets of a fluorescent taxoid inducing cell death. Cell Motil Cytoskeleton 2001; 49:1–15PubMedCrossRef Abal M, Souto AA, Amat-Guerri F, Acuna AU, Andreu JM, Barasoain I. Centrosome and spindle pole microtubules are main targets of a fluorescent taxoid inducing cell death. Cell Motil Cytoskeleton 2001; 49:1–15PubMedCrossRef
43.
Zurück zum Zitat Bucci M, Wente SR. In vivo dynamics of nuclear pore complexes in yeast. J Cell Biol 1997; 136:1185–99PubMedCrossRef Bucci M, Wente SR. In vivo dynamics of nuclear pore complexes in yeast. J Cell Biol 1997; 136:1185–99PubMedCrossRef
Metadaten
Titel
Short-Term Exposure of Cancer Cells to Micromolar Doses of Paclitaxel, with or without Hyperthermia, Induces Long-Term Inhibition of Cell Proliferation and Cell Death In Vitro
verfasst von
John Michalakis
Spyros D. Georgatos
Eelco de Bree
Hara Polioudaki
John Romanos
Vassilis Georgoulias
Dimitris D. Tsiftsis
Panayiotis A. Theodoropoulos
Publikationsdatum
01.03.2007
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 3/2007
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-006-9305-4

Weitere Artikel der Ausgabe 3/2007

Annals of Surgical Oncology 3/2007 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.